Nippon Chemiphar
4539.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥33.1bn | ¥32.6bn | ¥30.7bn | ¥31.6bn | ¥32.5bn | ¥31.5bn |
| Operating income | ¥179m | ¥606m | −¥494m | −¥241m | ¥825m | ¥564m |
| Ordinary income | ¥227m | ¥443m | −¥219m | ¥58m | ¥1.0bn | ¥582m |
| Net income (owners) | ¥198m | ¥294m | −¥180m | ¥339m | ¥700m | ¥495m |
| Total assets | ¥50.0bn | ¥49.9bn | ¥49.5bn | ¥48.6bn | ¥49.5bn | ¥47.1bn |
| Net assets / equity | ¥19.5bn | ¥19.2bn | ¥18.5bn | ¥18.5bn | ¥18.5bn | ¥18.0bn |
| Operating cash flow | ¥620m | −¥265m | ¥296m | −¥916m | ¥1.8bn | ¥1.5bn |
| EPS (basic) | ¥54.81 | ¥81.72 | ¥-50.14 | ¥94.07 | ¥194.33 | ¥137.75 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 6
| Period | Form | Figures |
|---|---|---|
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 47 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Medicine | ¥31.9bn | ¥187m |
| Other segments | ¥1.2bn | −¥7m |
| Adjustments & eliminations | — | — |
| Total | ¥33.1bn | ¥179m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.